vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $164.7M, roughly 1.2× PTC THERAPEUTICS, INC.). Axsome Therapeutics, Inc. runs the higher net margin — -14.6% vs -82.0%, a 67.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -22.7%). Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-36.6M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -11.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
AXSM vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $164.7M |
| Net Profit | $-28.6M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | -43.3% |
| Net Margin | -14.6% | -82.0% |
| Revenue YoY | 65.0% | -22.7% |
| Net Profit YoY | 61.9% | -104.8% |
| EPS (diluted) | $-0.55 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $164.7M | ||
| Q3 25 | $171.0M | $211.0M | ||
| Q2 25 | $150.0M | $178.9M | ||
| Q1 25 | $121.5M | $1.2B | ||
| Q4 24 | $118.8M | $213.2M | ||
| Q3 24 | $104.8M | $196.8M | ||
| Q2 24 | $87.2M | $186.7M | ||
| Q1 24 | $75.0M | $210.1M |
| Q4 25 | $-28.6M | $-135.0M | ||
| Q3 25 | $-47.2M | $15.9M | ||
| Q2 25 | $-48.0M | $-64.8M | ||
| Q1 25 | $-59.4M | $866.6M | ||
| Q4 24 | $-74.9M | $-65.9M | ||
| Q3 24 | $-64.6M | $-106.7M | ||
| Q2 24 | $-79.3M | $-99.2M | ||
| Q1 24 | $-68.4M | $-91.6M |
| Q4 25 | -13.8% | -43.3% | ||
| Q3 25 | -27.0% | 1.4% | ||
| Q2 25 | -24.5% | -19.5% | ||
| Q1 25 | -46.9% | 82.5% | ||
| Q4 24 | -61.1% | -76.2% | ||
| Q3 24 | -59.8% | -27.7% | ||
| Q2 24 | -89.5% | -21.5% | ||
| Q1 24 | -89.7% | -21.6% |
| Q4 25 | -14.6% | -82.0% | ||
| Q3 25 | -27.6% | 7.5% | ||
| Q2 25 | -32.0% | -36.3% | ||
| Q1 25 | -48.9% | 73.7% | ||
| Q4 24 | -63.1% | -30.9% | ||
| Q3 24 | -61.7% | -54.2% | ||
| Q2 24 | -91.0% | -53.1% | ||
| Q1 24 | -91.1% | -43.6% |
| Q4 25 | $-0.55 | $-1.63 | ||
| Q3 25 | $-0.94 | $0.20 | ||
| Q2 25 | $-0.97 | $-0.83 | ||
| Q1 25 | $-1.22 | $10.04 | ||
| Q4 24 | $-1.54 | $-0.85 | ||
| Q3 24 | $-1.34 | $-1.39 | ||
| Q2 24 | $-1.67 | $-1.29 | ||
| Q1 24 | $-1.44 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $-205.3M |
| Total Assets | $689.8M | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $1.9B | ||
| Q3 25 | $325.3M | $1.7B | ||
| Q2 25 | $303.0M | $2.0B | ||
| Q1 25 | $300.9M | $2.0B | ||
| Q4 24 | $315.4M | $1.1B | ||
| Q3 24 | $327.3M | $1.0B | ||
| Q2 24 | $315.7M | $1.1B | ||
| Q1 24 | $331.4M | $884.8M |
| Q4 25 | $88.3M | $-205.3M | ||
| Q3 25 | $73.7M | $-155.8M | ||
| Q2 25 | $73.1M | $-206.5M | ||
| Q1 25 | $53.2M | $-185.8M | ||
| Q4 24 | $57.0M | $-1.1B | ||
| Q3 24 | $92.9M | $-1.1B | ||
| Q2 24 | $102.9M | $-980.2M | ||
| Q1 24 | $144.0M | $-893.9M |
| Q4 25 | $689.8M | $2.9B | ||
| Q3 25 | $669.3M | $2.6B | ||
| Q2 25 | $639.8M | $2.6B | ||
| Q1 25 | $596.7M | $2.7B | ||
| Q4 24 | $568.5M | $1.7B | ||
| Q3 24 | $561.5M | $1.8B | ||
| Q2 24 | $548.2M | $1.9B | ||
| Q1 24 | $545.7M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $-34.3M |
| Free Cash FlowOCF − Capex | $-18.7M | $-36.6M |
| FCF MarginFCF / Revenue | -9.6% | -22.3% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $-34.3M | ||
| Q3 25 | $1.0M | $-66.3M | ||
| Q2 25 | $-32.4M | $-58.3M | ||
| Q1 25 | $-43.4M | $870.1M | ||
| Q4 24 | $-26.2M | $-30.0M | ||
| Q3 24 | $-18.6M | $-77.0M | ||
| Q2 24 | $-30.1M | $-71.5M | ||
| Q1 24 | $-53.5M | $70.8M |
| Q4 25 | $-18.7M | $-36.6M | ||
| Q3 25 | $988.0K | $-69.7M | ||
| Q2 25 | $-32.4M | $-59.6M | ||
| Q1 25 | $-43.7M | $868.4M | ||
| Q4 24 | $-26.2M | $-33.8M | ||
| Q3 24 | $-18.7M | $-77.5M | ||
| Q2 24 | $-30.2M | $-78.8M | ||
| Q1 24 | $-53.6M | $61.2M |
| Q4 25 | -9.6% | -22.3% | ||
| Q3 25 | 0.6% | -33.1% | ||
| Q2 25 | -21.6% | -33.3% | ||
| Q1 25 | -36.0% | 73.8% | ||
| Q4 24 | -22.1% | -15.8% | ||
| Q3 24 | -17.9% | -39.4% | ||
| Q2 24 | -34.6% | -42.2% | ||
| Q1 24 | -71.4% | 29.1% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
